228 related articles for article (PubMed ID: 35933650)
1. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.
Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Gonzalez-Padilla DA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011281. PubMed ID: 26798030
[TBL] [Abstract][Full Text] [Related]
4. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
Thrasher J; Bhargava A; Rees TM; Wang T; Guzman CB; Glass LC
Endocr Pract; 2015 Mar; 21(3):247-57. PubMed ID: 25370322
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
Pala L; Dicembrini I; Mannucci E
Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
[TBL] [Abstract][Full Text] [Related]
6. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
van Bon AC; Bode BW; Sert-Langeron C; DeVries JH; Charpentier G
Diabetes Technol Ther; 2011 Jun; 13(6):607-14. PubMed ID: 21457066
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
[TBL] [Abstract][Full Text] [Related]
8. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.
Beck RW; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Calhoun P
Diabetes Technol Ther; 2022 Oct; 24(10):681-696. PubMed ID: 36173235
[No Abstract] [Full Text] [Related]
12. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
Bode BW
Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
[TBL] [Abstract][Full Text] [Related]
13. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
Warren M; Bode B; Cho JI; Liu R; Tobian J; Hardy T; Chigutsa F; Phillip M; Horowitz B; Ignaut D
Diabetes Obes Metab; 2021 Jul; 23(7):1552-1561. PubMed ID: 33687783
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
[TBL] [Abstract][Full Text] [Related]
15. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials.
Kapur R; Mittra S; Tonpe G; P A; Raj P; Gudat U; Athalye SN
Expert Opin Biol Ther; 2024 Jun; 24(6):543-561. PubMed ID: 38934226
[TBL] [Abstract][Full Text] [Related]
17. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
[TBL] [Abstract][Full Text] [Related]
18. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
[TBL] [Abstract][Full Text] [Related]
20. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.
Karges B; Schwandt A; Heidtmann B; Kordonouri O; Binder E; Schierloh U; Boettcher C; Kapellen T; Rosenbauer J; Holl RW
JAMA; 2017 Oct; 318(14):1358-1366. PubMed ID: 29049584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
